Fighting challenges in surgery – together
Edwards Lifesciences is with you all the way. We’re committed to the patient, cardiac surgery, and to you—the surgeon. We are adapting to the changing needs in the industry and in the world. We innovate alongside you, listening and learning – dedicated to advances that help you fight the toughest challenges in surgery.
RESILIA tissue valve portfolio
RESILIA tissue* gives surgeons the freedom to offer a resilient tissue alternative that brings the quality-of-life benefits of tissue valves to patients.
Explore the Edwards RESILIA tissue aortic product below.
*No clinical data are available that evaluate the long-term impact of RESILIA tissue in patients. Additional clinical data for up to 10 years of follow-up are being collected to monitor the long-term safety and performance of RESILIA tissue.
Spotlight on RESILIA tissue
Tissue with a difference
A key challenge with pericardial tissue is structural valve deterioration (SVD), much of which is due to calcium buildup. RESILIA tissue is transformed to resist calcification differently. It offers enhanced anti-calcification technology that will potentially allow the valve to last longer than conventional bioprosthetic valves.*
Visit the RESILIA tissue pre-clinical and clinical data Inspiring Results page to learn about how the tissue is performing.
*RESILIA tissue tested against tissue from commercially-available bovine pericardial valves from Edwards in a juvenile sheet model. Flameng, et al. J Thorac Cardiovasc Surg 2015;149;340-5.
*No clinical data are available that evaluate the long-term impact of RESILIA tissue in patients. Additional clinical data for up to 10 years of follow-up are being collected to monitor the long-term safety and performance of RESILIA tissue.
